2380. Healthcare Resource Utilization for High-Risk Patients Treated With Dalbavancin in Physician Office Infusion Centers (POICs)

BACKGROUND: Medicare beneficiaries and patients (patients) ≥65 years comprise the highest risk for utilization of healthcare resources including emergency department (ED) visits and hospitalizations (hosp). Dalbavancin (DAL) is a long-acting lipoglycopeptide approved for treatment of bacterial skin...

Descripción completa

Detalles Bibliográficos
Autores principales: Luu, Quyen, Statner, Barry, Dretler, Robin H, Baker, H Barry, Metzger, Brian S, Hardin, Thomas C, Schroeder, Claudia P, Anglen, Lucinda J Van
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255471/
http://dx.doi.org/10.1093/ofid/ofy210.2033

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255471/
http://dx.doi.org/10.1093/ofid/ofy210.2033

Ejemplares similares